Josie Maran Argan Apothecary Daily Response Calming Treatment Lotion

Argan Apothecary Daily Response Calming Treatment Lotion

Product details

Description

A soothing cream containing tea tree and argan oil, used after cleansing on areas where blemishes are a concern.

  • Its lightweight texture spreads smoothly over the entire face.
  • It absorbs without feeling uneven and leaves skin feeling fresh and refined.
  • Comfortable to use even when skin is prone to irritation.
  • Ideal for focused care on areas where blemishes recur.

We strive to provide accurate product information. The information shown here was provided by the manufacturer, suppliers, and other sources and has not been verified by us. Please see our disclaimer.

How to use
1) After cleansing, refine the skin’s texture with toner. 2) Apply an appropriate amount to areas where blemishes are a concern or over the entire face. 3) Gently pat with your fingertips to help absorption. 4) Use with your favorite moisturizer as the final step morning and evening.
Brand / Product name
/ Argan Apothecary Daily Response Calming Treatment Lotion

What's in it?

Based on the full ingredient list: Expected benefits 8 items

Based on the full ingredient list: Potential concerns 7 items

Key features

  • Alcohol-free
  • EU allergen-free
  • Fragrance-free
  • Oil-free
  • Paraben-free
  • Silicone-free
  • Sulfate-free
  • Reef-safe
  • Fungal acne-safe
Argan Apothecary Daily Response Calming Treatment Lotion Find dupes

This information is based on the properties of individual ingredients in the full ingredient list and does not indicate the efficacy of the product itself or clinical results.

There are no survey responses for this product yet.

Ask the community

Viewduc users haven’t asked any questions about Argan Apothecary Daily Response Calming Treatment Lotion yet.

Ratings & reviews

0
0 reviews
  • 5 stars, 0 reviews, 0%
  • 4 stars, 0 reviews, 0%
  • 3 stars, 0 reviews, 0%
  • 2 stars, 0 reviews, 0%
  • 1 stars, 0 reviews, 0%
This product has no reviews yet.